Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech, Inc. develops and commercializes fertility-control products for managing animal pest populations, with current products focused on rat and mouse populations. Its product names include ContraPest, Evolve Rat, and Evolve Mouse, which are used within pest-management programs as alternatives or complements to traditional rodent-control methods.
Company news centers on Evolve commercialization, e-commerce and direct-to-consumer sales channels, Amazon marketplace management, field-study data on rodent activity, product approvals in international markets, quarterly and annual financial results, capital runway commentary, and executive leadership or board governance updates.
SenesTech, Inc. (SNES) announced that its innovative Elevate Bait System with ContraPest, the only EPA registered birth control for rats, is now available for purchase nationwide, including California. This system targets roof rats effectively, especially in agricultural settings. Since its initial launch, the system has gained rapid traction, and CEO Ken Siegel highlighted significant customer interest following approval from the California Department of Pesticide Regulation. The product aims to reduce rat populations, which can reproduce exponentially, with the potential to eliminate infestations more efficiently.
SenesTech, Inc. (SNES) has launched the Elevate Bait System, an innovative EPA-registered birth control solution for roof rats, now available for purchase in the U.S. The system is designed for deployment in elevated indoor spaces to effectively target and control rat populations. This follows successful trials, showing a 95% reduction in rat activity on poultry farms after using ContraPest. The system allows easy maintenance and has received EPA approval, except in California. This breakthrough aims to combat the rising roof rat populations causing significant property damage and health risks.
SenesTech (NASDAQ: SNES) reported a remarkable 122% increase in first-quarter 2022 sales, reaching approximately $195,000, compared to $88,000 the previous year. The launch of the Elevate Bait System™ with ContraPest is anticipated to enhance market penetration, particularly in agriculture, targeting above-ground rat infestations. Despite revenue growth, the company experienced a net loss of $(2.3) million, up from $(1.8) million in Q1 2021. Cash reserves stand at approximately $7.2 million. CEO Ken Siegel emphasized ongoing sales success and innovative market solutions.
SenesTech, Inc. (NASDAQ: SNES) will disclose its first quarter 2022 financial results on May 12, 2022, after market close. The company will hold a conference call at 5:00 pm ET the same day to discuss the results. SenesTech specializes in rodent fertility control through its product, ContraPest, aiming to reduce rat populations sustainably. For participation details, interested parties can dial (844) 308-3351 or access a live webcast on the company's investor relations website.
SenesTech, Inc. (NASDAQ: SNES) will participate in the Lytham Partners Spring 2022 Investor Conference from April 4-7, 2022. A webcast presentation will be available on April 4 at 11:00 AM ET on the company's website and can be archived for later viewing. Management will also hold virtual one-on-one meetings during the event. SenesTech specializes in rodent fertility control and offers ContraPest, the first U.S. EPA-registered contraceptive for rats, aiming to minimize pest populations sustainably.
SenesTech (NASDAQ: SNES) reported a significant increase in its 2021 revenue, reaching approximately $600,000, up 113% year-over-year. Product sales surged 123%, supported by expanded deployments of ContraPest® in various sectors, including government and wildlife preservation. The company's customer base grew by 300%. Despite a net loss of $(8.3) million, cash reserves stood at approximately $9.3 million. The recent EPA approval of the Elevate Bait System™ is expected to enhance market penetration further.
SenesTech, Inc. (NASDAQ: SNES) is set to release its financial results for the fourth quarter and fiscal year 2021, concluding on December 31, 2021, after market close on March 29, 2022. A conference call will follow at 5:00 PM ET on the same day, allowing stakeholders to review the results. The company specializes in rodent fertility control, offering ContraPest, the only EPA-registered contraceptive targeting male and female rats. This innovative solution aims to significantly reduce rat populations sustainably.
SenesTech, Inc. (SNES) has announced the EPA approval and launch of its Elevate Bait System with ContraPest, targeting rat infestations in above-ground locations. This innovative bait system allows for easy deployment in settings such as barns and granaries, significantly reducing servicing time with its design for quick bottle replacement. With ContraPest's proven ability to reduce rat populations by 60-90%, the company expects enhanced sales, particularly in agriculture, as state registrations progress for a mid-April shipping date.
SenesTech, Inc. (NASDAQ: SNES) has announced the deployment of its ContraPest® product at a 2,500-bed medium security correctional facility, marking a significant first for pest control in major correctional settings.
ContraPest, a non-lethal rodent birth control solution, is designed to tackle complex challenges in correctional environments, achieving population reduction in rats by at least 94%. The product is capable of being deployed in various locations and seeks to expand within institutional settings. CEO Ken Siegel noted the importance of this advancement for pest management professionals.
SenesTech, Inc. (NASDAQ: SNES) announced the deployment of its rodent fertility control product, ContraPest®, at Safari West Wildlife Preserve in California. This initiative is part of a broader eco-friendly pest management strategy, crucial for controlling rat populations that can rapidly reproduce in safe environments. ContraPest offers a non-lethal solution that has proven to reduce rat populations by at least 94%. The product is now increasingly being adopted in zoos and sanctuaries across the U.S., with expectations of continued growth in this market.